Literature DB >> 19714598

Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al.

Manuel Ramos-Casals, Candido Díaz-Lagares, Munther A Khamashta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19714598     DOI： 10.1002/art.24726

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  11 in total

Review 1.  Future prospects in biologic therapy for systemic lupus erythematosus.

Authors:  William Stohl
Journal:  Nat Rev Rheumatol       Date:  2013-09-10       Impact factor: 20.543

2.  Defining biological subsets in systemic lupus erythematosus: progress toward personalized therapy.

Authors:  Nailú Angélica Sinicato; Mariana Postal; Simone Appenzeller; Timothy B Niewold
Journal:  Pharmaceut Med       Date:  2017-01-25

3.  Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.

Authors:  Maria Trachana; Artemis Koutsonikoli; Evagelia Farmaki; Nikoleta Printza; Vasiliki Tzimouli; Fotios Papachristou
Journal:  Rheumatol Int       Date:  2011-11-19       Impact factor: 2.631

4.  The discovery and development of belimumab: the anti-BLyS-lupus connection.

Authors:  William Stohl; David M Hilbert
Journal:  Nat Biotechnol       Date:  2012-01-09       Impact factor: 54.908

Review 5.  Rituximab therapy in lupus nephritis: current clinical evidence.

Authors:  Manuel Ramos-Casals; Candido Diaz-Lagares; Maria-Jose Soto-Cardenas; Pilar Brito-Zeron; María-José Cuadrado; Giovanni Sanna; Laura Bertolaccini; Munther A Khamashta
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

Review 6.  Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis.

Authors:  Lan Lan; Fei Han; Jiang-hua Chen
Journal:  J Zhejiang Univ Sci B       Date:  2012-09       Impact factor: 3.066

7.  Outcomes of rituximab therapy in refractory lupus: A meta-analysis.

Authors:  Fatma Alshaiki; Elaf Obaid; Abdulqader Almuallim; Rabab Taha; Hadeel El-Haddad; Hani Almoallim
Journal:  Eur J Rheumatol       Date:  2018-02-13

Review 8.  Rituximab and lupus--a promising pair?

Authors:  Sara Linder Ekö; Ronald F van Vollenhoven
Journal:  Curr Rheumatol Rep       Date:  2014       Impact factor: 4.592

9.  New treatment options for lupus - a focus on belimumab.

Authors:  Laurent Chiche; Noémie Jourde; Guillemette Thomas; Nathalie Bardin; Charleric Bornet; Albert Darque; Julien Mancini
Journal:  Ther Clin Risk Manag       Date:  2012-01-26       Impact factor: 2.423

Review 10.  B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.

Authors:  Venkat Reddy; David Jayne; David Close; David Isenberg
Journal:  Arthritis Res Ther       Date:  2013-02-11       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.